On the stock market since 2010, it operates in the world of health and science. It has 191 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 536% a year over the last 4 years. Red columns mark years that ended in a loss.
The two sides balance each other out — the picture is neither a safety net nor an alarm.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
The cash-and-debt balance is neither shiny nor alarming.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 50% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 52% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 1,583% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 38/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, CRMD sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CRMD is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.